Johnson & Johnson’s posdinemab receives FDA fast track designation for its Alzheimer’s treatment
by
Contributor since / Followers
Contributor since / Followers
1 day ago
Rasi Bhadramani
- Johnson & Johnson (NYSE:JNJ) announced that the U.S. Food and Drug Administration has granted Fast Track designation to posdinemab to treat patients with early Alzheimer’s disease in the Phase 2b “AuTonomy” study.
- Posdinemab is the second Fast Track designation granted